TYR and melanoma: One example is the Eastern Cooperative Oncology Group Phase II Trial E1696 [33], where a mix of peptides containing multiple epitopes derived from three lineage-restricted antigens MART-1, gp100, and tyrosinase was administered in patients with metastatic unresectable melanoma in combination with IFNα or GM-CSF.